medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Número 5

<< Anterior Siguiente >>

Ann Hepatol 2018; 17 (5)


Salidroside and Curcumin Formula Prevents Liver Injury in Nonalcoholic Fatty Liver Disease in Rats

Li Hong-Shan, Ying H, He Zhe-Yun

Idioma: Ingles.
Referencias bibliográficas: 27
Paginas: 769-778
Archivo PDF: 1110.18 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Rinella ME, Sanyal AJ. Management of NAFLD: a stagebased approach. Nat Rev Gastroenterol Hepatol 2016; 13: 196-205.

  2. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010; 28: 155-61.

  3. Bhala N, Jouness RI, Bugianesi E. Epidemiology and natural history of patients with NAFLD. Curr Pharm Des 2013; 19: 5169-76.

  4. Fan JG, Zhu J, Li XJ, Chen L, Li L, Dai F, Li F, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol 2005; 43: 508-14.

  5. Jimba S, Nakagami T, Takahashi M, Wakamatsu T, Hirota Y, Iwamoto Y, Wasada T. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 2005; 22: 1141-5.

  6. Kwon YM, Oh SW, Hwang SS, Lee C, Kwon H, Chung GE. Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in Korean adults. Am J Gastroenterol 2012; 107: 1852-8.

  7. Brouwers B, Schrauwen-Hinderling VB, Jelenik T, Gemmink A, Havekes B, Bruls Y, Dahlmans D, et al. Metabolic disturbances of non-alcoholic fatty liver resemble the alterations typical for type 2 diabetes. Clin Sci (Lond) 2017.

  8. Engin A. Non-Alcoholic Fatty Liver Disease. Adv Exp Med Biol 2017; 960: 443-67.

  9. Par A, Par G. Advances in the pathogenesis of non alcoholic fatty liver disease. Orv Hetil 2017; 158: 882-94.

  10. Zhao SP, Wu ZS, Chen Y, Liang X, Bao L, Li P, Sun RR, et al. Protective effect of Hua Tan Qu Shi decoction against liver injury in rats with nonalcoholic fatty liver disease. Biomed Pharmacother 2017; 91: 181-90.

  11. Cheng F, Ma C, Wang X, Zhai C, Wang G, Xu X, Mu J, et al. Effect of traditional Chinese medicine formula Sinisan on chronic restraint stress-induced nonalcoholic fatty liver disease: a rat study. BMC Complement Altern Med 2017; 17: 203.

  12. Li H, Zhu D, Ying H, Li D. Effects of curcumin and salidroside combination on fatty liver induced by simple high fat diet in rats. Journal of Chinese Medicinal Materials 2015; 38: 1027-9.

  13. Li H, Ying H, Hu A, Li D, Hu Y. Salidroside Modulates Insulin Signaling in a Rat Model of Nonalcoholic Steatohepatitis. Evid Based Complement Alternat Med 2017; 2017: 9651371.

  14. Fatty liver and alcoholic liver disease group of Chinese Medical Association liver disease Branch. Guideline for diagnosis and treatment of nonalcoholic fatty liver disease. Chin J Hepatol 2010; 18: 163-6.

  15. Li H, Ying H, Hu A, Hu Y, Li D. Therapeutic Effect of Gypenosides on Nonalcoholic Steatohepatitis via Regulating Hepatic Lipogenesis and Fatty Acid Oxidation. Biol Pharm Bull 2017; 40: 650-7.

  16. Huiqing L, Jiaen Y, Jinmo T, Chuncheng W, Hongshan L, Shaodong C. Optimization of dosage ratio of chlorogenic acid and gardenia glycosides in the treatment of rats with fatty liver disease induced by high-fat feed. J Tradit Chin Med 2016; 36: 683-8.

  17. Corey KE, Chalasani N. Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials? Hepatology 2011; 54: 1503-5.

  18. Cheng J, Joyce A, Yates K, Aouizerat B, Sanyal AJ. Metabolomic profiling to identify predictors of response to vitamin E for non-alcoholic steatohepatitis (NASH). PLoS One 2012; 7: e44106.

  19. Indiveri C, Iacobazzi V, Tonazzi A, Giangregorio N, Infantino V, Convertini P, Console L, et al. The mitochondrial carnitine/ acylcarnitine carrier: function, structure and physiopathology. Mol Aspects Med 2011; 32: 223-33.

  20. Day CP, James OF. Steatohepatitis: a tale of two hits? Gastroenterology 1998; 114: 842-5.

  21. Sasaki Y, Kozaki A, Hatano M. Link between light and fatty acid synthesis: thioredoxin-linked reductive activation of plastidic acetyl-CoA carboxylase. Proc Natl Acad Sci USA 1997; 94: 11096-101.

  22. Lee JH, Jung IR, Choi SE, Lee SM, Lee SJ, Han SJ, Kim HJ, et al. Toxicity generated through inhibition of pyruvate carboxylase and carnitine palmitoyl transferase-1 is similar to high glucose/palmitate-induced glucolipotoxicity in INS-1 beta cells. Mol Cell Endocrinol 2014; 383: 48-59.

  23. Ha SK, Kim J, Chae C. Role of AMP-activated protein kinase and adiponectin during development of hepatic steatosis in high-fat diet-induced obesity in rats. J Comp Pathol 2011; 145: 88-94.

  24. Nammi S, Roufogalis BD. Light-to-moderate ethanol feeding augments AMPK-alpha phosphorylation and attenuates SREBP-1 expression in the liver of rats. J Pharm Pharm Sci 2013; 16: 342-51.

  25. Luo W, Xu Q, Wang Q, Wu H, Hua J. Effect of modulation of PPAR-gamma activity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease. Sci Rep 2017; 7: 44612.

  26. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015; 313: 2263-73.

  27. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8: 521-533, viii.




2020     |     www.medigraphic.com